{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-039554","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2023-03-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.299771+00:00","generated_at":"2026-06-17T08:05:48.812279+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"NRx Pharma reports FY2022 net loss $39.8M; advances NRX-101 trials, issues going concern warning","bullets":["Net loss $39.8M for FY2022 vs $93.1M prior year; R&D $17.0M, G&A $27.4M.","Cash $20.1M at Dec 31, 2022; raised $2.9M in March 2023 registered direct offering.","DSMB cleared NRX-101 Phase 2b/3 trial for suicidal treatment-resistant bipolar depression; topline data expected 4Q2023.","FDA suggested broader outpatient indication for NRX-101; safety database of 1,500 patients required.","Going concern doubt: no revenue, $11M note to Streeterville Capital may require cash repayment; additional financing needed."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-039554","json":"https://secwatch.observer/filing/0001104659-23-039554.json","markdown":"https://secwatch.observer/filing/0001104659-23-039554.md","text":"https://secwatch.observer/filing/0001104659-23-039554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/0001104659-23-039554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/tm2311032d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T08:05:48.812279+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9957f50853e1ab9794b811880daebd5d3143c620","claim":"NRX Pharmaceuticals, Inc. reported financial results for full year and fourth quarter ended December 31, 2022.","evidence_excerpt":"On March 30, 2023, the Company announced its financial results for the full year and fourth quarter ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923039554/0001104659-23-039554-index.htm","confidence":0.7,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full year and fourth quarter ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}